News & Events

Xigen announces the online publication of successful Phase II results for its lead compound Brimapitide (XG-102) in the American Journal of Ophthalmology. - January 2017

Xigen announced that in the world Health Organization’s latest publication (“pre publication copy”) of International Nonproprietary names for pharmaceutical substances (INN), brimapitide has been confirmed for its molecule which was previously designated as XG-102. - April 2016

AAIC (Alzheimer’s Association International Conference) - July 24, 2016 in Toronto
Oral presentation - Sarah Gourmaud
“Cognitive and neuroprotective  effects of JNK inhibition in 5XFAD mice”

ERA-EDTA (European Renal Association – European Dialysis and Transplant Association) - May 21 – 24, 2016 in Vienna
Poster presentation – Chiara Alfarano
“Effect of JNK inhibitor in a rat model of renal ischemia-reperfusion injury”
“Effects of JNK inhibitor on puromycin aminonucleoside-induced nephropathy in rats”